The drug pipeline of Priavoid is composed of 7 compounds at various stages of pharmaceutical development within 6 diseases:

  • Alzheimer’s disease
  • Neuropathic pain
  • Amyotrophic lateral sclerosis
  • Tauopathies
  • Huntington’s disease
  • Parkinson’s disease



is the most advanced drug in our pipeline for the causal treatment of Alzheimer’s disease (AD).


Thus, PRI-002 has three unique selling propositions (USPs):


New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Intervention Strategy

Priavoid developed a completely new therapeutic strategy for the causal treatment of Alzheimer’s disease.  The orally available D-peptide PRI-002  permeates the blood-brain barrier effectively, does not interfere with formation or clearance of non-toxic Aß monomers, but specifically eliminates cytotoxic  Aß-oligomers.



Partnering is a key component of Priavoids strategy

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice